BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260430T190000
DTEND;TZID=Africa/Nairobi:20260430T203000
DTSTAMP:20260603T201834
CREATED:20260526T192028Z
LAST-MODIFIED:20260526T194041Z
UID:41701-1777575600-1777581000@kesho-kenya.org
SUMMARY:Multidisciplinary Management of Testicular Cancer
DESCRIPTION:Moderator: Dr. Muigai Mararo\nSpeakers: Dr. Dedan Opondo\, Dr. Joseph Abuodha\, Dr. George Ogweno\nDate: 30 April 2026\n\nThis session marked Testicular Cancer Awareness Month with a multidisciplinary discussion on diagnosis\, primary management\, advanced disease\, relapse and fertility preservation. \nA central theme was that testicular cancer is highly curable when investigated and managed promptly\, but cure depends on disciplined staging and risk stratification. Dr. Dedan Opondo outlined the importance of early clinical recognition\, scrotal ultrasound\, serum tumour markers\, cross-sectional imaging and radical inguinal orchiectomy. The session reinforced that suspected testicular cancer should not be delayed\, particularly because some germ cell tumours can progress rapidly. \nStaging was presented as a practical foundation for management. Tumour markers such as AFP\, beta-HCG and LDH\, together with nodal imaging and histology\, help distinguish seminomatous from non-seminomatous disease and guide decisions on surveillance\, chemotherapy\, radiotherapy and retroperitoneal lymph node dissection. The discussion also highlighted the technical and fertility-related implications of retroperitoneal surgery in young men. \nDr. Joseph Abuodha reviewed advanced and relapsed disease\, emphasising that treatment remains strongly anchored in surgery\, cisplatin-based chemotherapy\, radiotherapy and surveillance rather than newer targeted or immunotherapy approaches. Across stages\, the emphasis was on matching intensity to risk—avoiding both overtreatment and undertreatment—while recognising that even metastatic disease can remain curable with the right treatment strategy. \nDr. George Ogweno brought fertility preservation into the core of cancer care. He underscored the need for early oncofertility counselling\, sperm banking where possible before treatment\, and stronger collaboration between oncology\, urology\, fertility specialists\, laboratories and counsellors. The discussion also reflected Kenya’s service realities\, including limited fertility centres and the need for clearer pathways\, consent and long-term storage planning. \nAcross the session\, a consistent message emerged: testicular cancer care must protect both survival and survivorship. \nKey Takeaways\n\nEarly recognition\, tumour markers\, imaging and radical inguinal orchiectomy are central to initial management.\nRisk stratification using histology\, TNM stage and post-operative markers guides treatment intensity.\nSeminoma and non-seminoma pathways differ and should not be managed interchangeably.\nCisplatin-based chemotherapy remains central in advanced and relapsed disease.\nSurveillance is appropriate only when reliable follow-up is possible.\nFertility counselling and sperm preservation should be discussed as early as possible.
URL:https://kesho-kenya.org/event/multidisciplinary-management-of-testicular-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/Multidisciplinary-Management-of-Testicular-Cancer.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260507T190000
DTEND;TZID=Africa/Nairobi:20260507T203000
DTSTAMP:20260603T201834
CREATED:20260525T193909Z
LAST-MODIFIED:20260525T210319Z
UID:41667-1778180400-1778185800@kesho-kenya.org
SUMMARY:From Data to Discovery: Leveraging Registries and Clinical Insights to Advance Research
DESCRIPTION:Moderator: Rebecca Mwakichako\nDate: 7th May 2026\nSpeakers: Dr. Thomas Chatzikonstantinou\, Ms. Anne Korir \nThis session examined how routine clinical data can be transformed into meaningful research evidence\, with a focus on real-world data\, clinical registries and everyday documentation as a foundation for local oncology research. \nA central theme was the value of real-world evidence as a complement to randomized controlled trials. Dr. Thomas Chatzikonstantinou outlined how registries and clinical databases can help answer questions on treatment patterns\, long-term outcomes\, low-prevalence biomarkers\, health economics and implementation across diverse settings. He emphasized that good research begins with realistic questions\, clear endpoints and attention to data quality. \nMs. Anne Korir grounded the discussion in the Kenyan cancer registry experience\, highlighting how paper files\, unstructured notes\, missing staging information\, weak follow-up documentation and inconsistent residence or risk-factor data can limit the research value of clinical records. She underscored the need for standardization\, digitization\, regular data cleaning and ethical governance. \nAcross the session\, a consistent message emerged: every clinical encounter can contribute to discovery when documentation is structured\, complete and designed with future learning in mind. \n  Key Takeaways \n\nReal-world data complements clinical trials by showing how care is delivered in routine practice.\nRoutine clinical notes can generate locally relevant oncology research questions.\nStandardized documentation is essential for usable research and registry data.\nCancer registries remain critical for surveillance\, policy and outcome tracking.\nCollaboration between clinicians\, registries and research institutions can strengthen local evidence generation.\n\n  \n 
URL:https://kesho-kenya.org/event/from-data-to-discovery-leveraging-registries-and-clinical-insights-to-advance-research/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/From-Data-to-Discovery.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260514T190000
DTEND;TZID=Africa/Nairobi:20260514T203000
DTSTAMP:20260603T201834
CREATED:20260525T203403Z
LAST-MODIFIED:20260525T210044Z
UID:41670-1778785200-1778790600@kesho-kenya.org
SUMMARY:Melanoma Care in Practice: Integrating Dermatology\, Surgery & Oncology
DESCRIPTION:Moderator: Dr Stephen Chege\nDate: 14th May 2026\nSPEAKERS: Dr. Hannah Wanyika\, Dr. Esther Gathura\, Dr. Angela McLigeyo \nThis session examined melanoma care across the clinical pathway\, from recognition of suspicious skin lesions to biopsy\, excision\, reconstruction\, staging and systemic treatment. \nA central theme was the importance of early suspicion and timely tissue diagnosis. Dr. Hannah Wanyika highlighted practical indications for biopsy\, including new or changing pigmented lesions\, non-healing ulcers\, evolving moles and lesions that differ from surrounding skin. The discussion reinforced the use of the ABCDE approach and the “ugly duckling” sign\, while emphasizing that changing lesions on the palms\, soles\, nails and scalp should not be dismissed. \nDr. Esther Gathura explored the surgical and reconstructive dimensions of melanoma care\, particularly the realities of acral melanoma\, which is common in African populations and often presents late. She emphasized the role of mapping biopsies\, Breslow thickness\, ulceration\, nodal assessment and multidisciplinary planning in balancing oncologic safety with function\, especially for weight-bearing areas of the foot. \nDr. Angela McLigeyo outlined the major advances in systemic therapy for advanced melanoma\, including immune checkpoint inhibitors\, targeted therapy and emerging treatment strategies. While immunotherapy has transformed outcomes globally\, the session also acknowledged access\, affordability and the urgent need for local data to guide treatment decisions in Kenya and the region. \nAcross the session\, a consistent message emerged: optimal melanoma care depends on early recognition\, accurate biopsy\, careful staging\, function-preserving surgery and realistic access to effective systemic therapy. \nKey Takeaways \n\nChanging pigmented lesions\, non-healing ulcers and suspicious nail or acral lesions require timely biopsy.\nThe ABCDE rule and “ugly duckling” sign remain useful tools in clinical assessment.\nAcral melanoma presents distinct diagnostic and surgical challenges in African settings.\nSurgical management must balance clear margins\, staging and functional reconstruction.\nImmunotherapy and targeted treatment have changed advanced melanoma care\, but access and local evidence remain key challenges.
URL:https://kesho-kenya.org/event/melanoma-care-in-practice-integrating-dermatology-surgery-oncology/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Melanoma-Care.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260521T190000
DTEND;TZID=Africa/Nairobi:20260521T203000
DTSTAMP:20260603T201834
CREATED:20260525T210458Z
LAST-MODIFIED:20260526T194356Z
UID:41677-1779390000-1779395400@kesho-kenya.org
SUMMARY:Bladder Cancer Care
DESCRIPTION:SPEAKERS: Dr. Patrick Mbuthia\, Dr. Helena Musau\, Dr Mohammed Ezzi\nDate: 21st May 2026\nModerator: Dr. Sitna Mwanzi \nThis session examined bladder cancer through a multidisciplinary lens\, bringing together surgical\, radiotherapeutic and systemic treatment perspectives across the continuum of care. \nA central theme was the need for accurate staging and risk-adapted management. Dr. Patrick Mbuthia discussed the role of transurethral resection of bladder tumour (TURBT) in diagnosis\, staging and treatment\, particularly for non-muscle invasive disease. The importance of complete resection\, adequate detrusor muscle in the specimen\, careful imaging and attention to complications was emphasized as central to subsequent treatment decisions. \nDr. Helena Musau highlighted the evolving role of radiotherapy in bladder preservation\, especially through tri-modality therapy combining maximal TURBT\, concurrent chemoradiation and structured response assessment. The discussion also addressed patient selection\, surveillance\, salvage options\, palliative radiotherapy for symptoms\, and the value of newer radiotherapy techniques in reducing toxicity while preserving quality of life. \nDr. Mohammed Ezzi reviewed systemic treatment across non-muscle invasive\, muscle invasive and metastatic bladder cancer. He outlined the role of intravesical therapy\, BCG\, cisplatin eligibility\, immunotherapy\, maintenance strategies and emerging options such as antibody-drug conjugates and targeted agents\, while noting that cost and availability continue to shape real-world treatment in Kenya. \nAcross the session\, a consistent message emerged: improving bladder cancer outcomes requires timely diagnosis\, high-quality TURBT\, multidisciplinary decision-making and treatment pathways that reflect both evidence and local access reality. \nKey Takeaways \n\nBladder cancer management depends on accurate staging and distinction between non-muscle invasive and muscle invasive disease.\nHigh-quality TURBT with adequate muscle sampling is central to diagnosis and treatment planning.\nTrimodality therapy offers bladder preservation for carefully selected patients.\nSystemic therapy is rapidly evolving with immunotherapy\, maintenance approaches and antibody-drug conjugates.\nLocal data are needed to address African patterns of disease\, including schistosomiasis-associated squamous cell carcinoma.\n\n 
URL:https://kesho-kenya.org/event/bladder-cancer-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Bladder-Cancer-Care-e1779824625799.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260528T190000
DTEND;TZID=Africa/Nairobi:20260528T203000
DTSTAMP:20260603T201834
CREATED:20260525T190142Z
LAST-MODIFIED:20260529T182745Z
UID:41658-1779994800-1780000200@kesho-kenya.org
SUMMARY:The Brain Tumour Journey
DESCRIPTION:Speakers: Dr. Michael Magoha; Dr. Sarah Muma; Dr. Parmenas Minda Okemwa\nModerator: Mr. David L. Oluoch-Olunya \nThe Brain Tumour Journey brought together neurosurgery\, paediatric haemato-oncology and neuropathology perspectives to examine how multidisciplinary collaboration can improve care for patients with brain tumours. The session positioned brain tumour management as a continuum\, from first symptoms and referral to surgery\, pathology\, oncology treatment\, rehabilitation\, follow-up and family support. \nDr. Michael Magoha opened the session by reframing the brain tumour journey around the patient experience. He noted that brain tumours often carry fear and uncertainty\, yet they are not a single diagnosis or a uniform prognosis. With more than 150 tumour types and subtypes\, the patient’s pathway can vary widely. His presentation highlighted the role of patient navigation in helping individuals move through imaging\, surgery\, pathology\, endocrine review\, oncology care and long-term follow-up without being lost in fragmented systems. \nDr. Sarah Muma focused on the multidisciplinary management of childhood brain tumours in Kenya. She highlighted that brain and CNS tumours appear under-recognised in local and African childhood cancer data\, suggesting delays in diagnosis and referral. Children may present with persistent headaches\, vomiting\, visual changes\, seizures\, gait or coordination problems\, abnormal head growth\, behavioral changes or endocrine-related symptoms. The discussion emphasized the need for a higher index of suspicion\, especially when symptoms are progressive\, recurrent or not responding as expected. \nThe session also examined Kenyan system-level challenges\, including limited access to timely imaging\, prolonged pathways between surgery and radiotherapy\, scarcity of formal paediatric neuro-oncology programs and treatment abandonment. Dr. Muma described the value of neuro-oncology multidisciplinary clinics\, where patients and families can receive coordinated input from neurosurgery\, oncology\, radiology\, pathology\, rehabilitation\, counselling and navigation teams within a more structured care pathway. \nDr. Parmenas Minda Okemwa closed the presentations by discussing the principles and diagnostic challenges of brain tumour pathology. He emphasized that pathology remains the gold standard for diagnosis\, but modern brain tumour care increasingly depends on integrated reporting that combines clinical context\, radiology\, histology\, immunohistochemistry and molecular testing. His presentation underscored the need for adequate tissue sampling\, stronger neuropathology capacity\, expanded diagnostic panels\, molecular testing access and regular multidisciplinary tumour board discussions. \nAcross the session\, the message was clear: improving brain tumour outcomes requires coordinated systems\, not isolated excellence. Timely diagnosis\, accurate pathology\, surgical expertise\, oncology planning\, patient navigation\, rehabilitation and survivorship support must work together if patients are to receive care that is clinically sound\, humane and sustainable. \nKey Takeaways\n\nBrain tumour care is a journey\, not a single event. Patients often require coordinated input across imaging\, surgery\, pathology\, oncology treatment\, rehabilitation and follow-up.\nPatient navigation can reduce fragmentation. Navigators help patients and families move through complex health systems and reduce the risk of missed appointments\, delayed reviews or incomplete follow-up.\nChildren may present with subtle or progressive symptoms. Persistent headaches\, seizures\, visual changes\, gait problems\, behavioural changes or endocrine symptoms should prompt a high index of suspicion.\nMultidisciplinary clinics can shorten delays. Same-day or coordinated review by several specialists can improve treatment planning and reduce the burden on families.\nAccurate diagnosis depends on integrated pathology. Histology remains central\, but immunohistochemistry and molecular testing increasingly guide classification\, prognosis and treatment options.\nKenya’s neuro-oncology systems are advancing but need strengthening. Referral pathways\, registries\, specialist training\, diagnostic capacity\, molecular testing access and survivorship systems remain key priorities.
URL:https://kesho-kenya.org/event/advancing-care-through-multidisciplinary-collaboration/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/WhatsApp-Image-2026-05-28-at-3.56.29-PM-1-e1780079236823.jpeg
END:VEVENT
END:VCALENDAR